Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,970,294

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $102.37 -0.21 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (202 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are Investors Undervaluing Cardinal Health (CAH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Zacks Analyst Blog Highlights McDonald's, W.W. Grainger and Cardinal Health

by Zacks Equity Research

McDonald's, W.W. Grainger and Cardinal Health are included in this Analyst Blog.

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Tirthankar Chakraborty headshot

3 Top S&P 500 Stocks to Buy as Index Tastes 4200 Mark

by Tirthankar Chakraborty

Banking on recent strengths, investors should place their bets on sound stocks like McDonald's (MCD), W.W. Grainger (GWW) & Cardinal Health (CAH) that are poised to scale upward along with the broader S&P 500 Index.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists

by Zacks Equity Research

For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

by Zacks Equity Research

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.

Zacks.com featured highlights include Cardinal Health, Boyd Gaming, Ford Motor, NXP Semiconductors N.V and American International

by Zacks Equity Research

Cardinal Health, Boyd Gaming, Ford Motor, NXP Semiconductors N.V and American International are part of the Zacks Screen of the Week article.

Abbott's (ABT) New Pact to Advance Clinical Trials Diversity

by Zacks Equity Research

Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.

Here's Why You Should Retain Veeva Systems (VEEV) Stock Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

by Zacks Equity Research

Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.

Urmimala Biswas headshot

5 Attractive Value Picks Based on Discounted PEG

by Urmimala Biswas

Here are five stocks that meet our screening criteria - CAH, BYD, F, NXPI, AIG.

National Vision (EYE) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.

Here's Why You Should Retain Patterson Companies (PDCO) Stock Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Why You Should Buy The Cooper Companies (COO) Stock Now

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health

by Zacks Equity Research

NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.

Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations

by Zacks Equity Research

Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.

Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.

Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.

DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.

Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y

by Zacks Equity Research

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.

Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.